44-940G

antibody from Invitrogen Antibodies

Targeting: PAK3 bPAK, hPAK3, MRX30, MRX47

Provider product page for 44-940G

Western blot

Other assay

Antibody data

Antibody Data
Antigen structure
References [20]
Comments [0]
Validations
Western blot [2]
Other assay [17]

Submit

Product number: 44-940G - Provider product page
Provider: Invitrogen Antibodies
Product name: Phospho-PAK1/2/3 (Ser141) Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Storage: -20°C

PAK3 protein structure - 44-940G shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 N-alpha-PGP activates endothelial cell signaling through CXCR2. ( A to C ) HUVECs were serum-starved for 2 hours before stimulation with N-alpha-PGP (0.5 mg/ml) for indicated times, and activation of Rac1 (A) and phosphorylation of PAK (pPAK) and ERK (pERK) (B) and VE-cadherin (pVE-cad) (C) were determined by Western blot. Shown are representative Western blots together with quantification. Bar graphs show means +- SEM ( n = 3). * P < 0.05 relative to time 0 by one-way analysis of variance (ANOVA) with Tukey post-test. ( D ) HUVECs were untreated or treated with N-alpha-PGP (0.5 mg/ml) (30 min) alone or after pretreatment with 200 nM SB225002, and Rac1 activity and phosphorylation of ERK, PAK, and VE-cadherin were determined by Western blot. Shown are representative Western blots together with quantification. Bar graphs show means +- SEM ( n = 3). * P < 0.05 relative to time 0, # P < 0.05 relative to PGP by one-way ANOVA with Tukey post-test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 The effect of Pak inhibitors on Erk and Akt-S6 signaling pathways KT21 or Ben-Men cells were treated with inhibitors for 72 hours as described in Figure 2 . Following SDS/PAGE and transfer to PVDF membranes, expression levels of Pak, Mek, Erk, Akt, S6, and beta-Catenin were assessed by immunoblot using total and phospho-specific antibodies. GADPH was used as loading control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Nck (noncatalytic region of tyrosine kinase) 1 first SH3 domain regulates PAK2 (p21-activated kinase 2)-induced endothelial permeability. A , Schematic of Nck1 point mutations in each of the SH3 domains and the nomenclature used to inactivation of SH3 domains. B , Lysates from human aortic endothelial cells (HAECs) transiently transfected with Nck1 variants with inactivated SH3 domains. C and D , Flow-induced permeability using biotinylated gelatin/Alexa 647-streptavidin assay. 4',6-Diamidino-2-phenylindole (blue; nuclei), phalloidin (green; F-actin fibers), and streptavidin (red; exposed biotinylated gelatin) Images analyzed using NIS-Elements software from n=4. Scale bar=200 mum. Data were reported as box and whiskers with scatter plots and analyzed by Kruskal-Wallis test (* P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Generation and analysis of conditional Rosa26 -promoter-based expression alleles. a LR reaction performed between the pROSA26-DV1 vector and pEntry clone containing GST-PID* fragment to generate the Rosa26 targeting vector. SA is spice acceptor, PGK is phosphoglycerate kinase 1 promoter, and 3xpA is multimerized polyadenylation sequence in which loxP-PGK-neo-3xpA-loxP formed a LSL cassette. b Homologous recombination occurred between exon 1 and 2 of wild-type Rosa26 locus in G4 ES cells after electroporation. Black boxes represent the exons located at ROSA26 locus. c Knock-in targeted allele analyzed by PCR using both external primers (F1 and R1) and internal primers (F2 and R2). d Cre-mediated excision of intervening loxP flanked PGK-neo-3xpA (STOP) cassette resulted in the Rosa26 -locus-based expression of an exon1-GST-PID*-IRES-eGFP bi-cistronic fusion transcript. e Representative result of genotyping PCR analysis of tail biopsy DNA detecting the presence of fusion transcript by both external primers (F1 and R1, 1.2 kb) and internal primers (F2 and R2, 1.4 kb), in which #54 and #70 were mice revealing positive results. f Phase contrast image (left side) and green fluorescence image (right side) showing the same field of view of MEF cells derived from PID mice after Adeno-cre virus infection. Representative western blot of GFP, GST, Pak1, Phospho-Pak expression level in MEF cells after infection of Adeno-cre virus. Relative protein expression wa

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 6 Selective changes in PAK-1/2/3 activation and expression in the hippocampus of individuals with early, moderate, and severe Alzheimer disease (AD). (a) Brain tissues from age-matched normal (control), early AD, and severe AD subjects were obtained postmortem and immunostained with an antibody against phosphorylated PAK-1/2/3 (Ser141) or rabbit IgG control, followed by Alexa Fluor488 anti-rabbit secondary (green). Nuclei were visualized with DAPI staining, pseudo-colored red. Representative images ( n = 8 human cases per group) of pyramidal hippocampal neurons were captured on a laser-scanning confocal microscope using a 40x objective and a 2x (top panel) or 4x (middle panel) zoom. Bottom panel show neurons stained with phospho-PAK-1/2/3 (green), PDI (or mouse IgG control; red), and DAPI (blue) at 40x objective and a 2x zoom. Scale bar: 10 mum. (b) A total of 100 mug each of human hippocampal extracts from normal, early AD, moderate AD, and severe AD pathology was examined by western blot using total PAK-1/2/3 (61 kDa PAK-2, 68 kDa PAK-1/3; top immunoblot) and GAPDH (36 kDa; bottom immunoblot) antibodies. Top and middle panels show representative immunoblots and the bottom panel shows mean densitometry values (+- SEM) for each group ( F = 6.3; df 3,24; p = 0.0027) of combined immunoblots ( n = 7 human cases per group). PAK-1/2/3 densitometry is expressed graphically as a percentage of the ratio of PAK to GAPDH, with denotation of significance obtained from statistical analys